Targeted Oncology Staff

During a virtual Targeted Oncology Case-Based Roundtable event, Atish D. Choudhury, MD, PhD, discussed methods for treating patients with nonmetastatic prostate cancer with a group of peers.

Jaffer A. Ajani, MD led a discussion around biomarkers to consider when determining systemic therapy for patients with stage IV gastric adenocarcinoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Michael A. Carducci, MD, reviewed the results of the CARD trial to support his recommendation of cabazitaxel for the treatment of a 75-year-old man with metastatic castration-resistant prostate cancer.

The PROfound and TRITON2 clinical trials have demonstrated the benefit of the PARP inhibitors olaparib and rucaparib for the treatment of metastatic castration-resistant prostate cancer.

According to findings from a subgroup analysis of the TALAPRO-1 trial, men with heavily pretreated metastatic castration-resistant prostate cancer, with germline and/or homozygous tumor DNA damage response alterations are most likely to respond to talazoparib.

Helen Moon, MD, reviewed the data from the JAVELIN Bladder 100 trial, which support the use of avelumab as maintenance therapy for patients with metastatic bladder cancer.

Luis Raez, MD, Hdiscussed the case of a 59-year-old patient with RET-mutated lung cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Tanya Dorff, MD, discussed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.

During a Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, Ticiana Leal, MD, discussed the case of a patient with non–small cell lung cancer with a group of peers.

Karen L. Reckamp, discussed the progression-free survival benefit achieved with ramucirumab in patients with EGFR-positive lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Matthew Smith, MD, PhD, discussed genomic testing in prostate cancer with a group of peers.

Ravi Salgia, MD, PhD, discussed the case of a 59-year-old patient with non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, discussed the case of a 58-year-old patients with RET-mutated thyroid cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Rodolfo Bordoni, MD, discussed recent clinical trials in the extensive-stage small cell lung cancer space.

Melissa Alsina, MD, reviewed the treatment options for transplant-eligible multiple myeloma based on the case of a 52-year-old male patient.

Jessica Bauman, MD, reviewed data from the LIBRETTO-001 and ARROW trials which show the efficacy and safety of selpercatinib and pralsetinib for the treatment of patients with RET fusion-positive lung cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel P. Petrylak, MD, discussed the case of a 66-year-old woman with metastatic bladder cancer.

Ezra Cohen, MD, lead a discussion on the efficacy of cemiplimab-rwlc for the treatment of cutaneous squamous cell carcinoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Lori Wirth, MD, discussed the treatment patients with radioiodine-refractory differentiated thyroid cancer with a group of peers.

During a Targeted Oncology Case-Based Roundtable event, Joseph Mikhael, MD, discusses responses observed in transplant-eligible patients with multiple myeloma.

David Dingli, MD, PhD, discussed the case of a 51-year-old patients with transplant-eligible myeloma.

Andrew M. Evens, DO, MSc, considered the data supporting brentuximab vedotin with chemotherapy for the treatment of a patient with peripheral T-cell lymphoma.

An accelerated approval was granted by the FDA to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

During a virtual Targeted Oncology Case-Based Roundtable event, Kartik Konduri, MD, discussed the case of a 58-year-old patients with small cell lung cancer.

Thomas Hutson, DO, PharmD, discussed the case of a 66-year-old patient with bladder cancer during a virtual Targeted Oncology Case-Based Roundtable event.

Vivek Subbiah, MD, explored the treatment options for RET-fusion positive non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, lead a debate with a group of peers on second-line therapy options for patients with renal cell carcinoma.

Schlafen-11 expression may serve as a predictive biomarker for response to select treatments in patients with small cell lung cancer.

Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.